Denali Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-512.5M | $-422.8M | $-145.2M | $-326.0M | $-290.6M | $71.1M | $-197.6M | $-36.2M |
| Depreciation & Amortization | $11.2M | $7.8M | $16.7M | $10.4M | $8.6M | $8.5M | $8.0M | $7.4M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $99.6M | $102.9M | $108.1M | $99.8M | $85.2M | $50.4M | $38.4M | $18.8M |
| Net Cash from Operating Activities | $-412.6M | $-347.7M | $-358.0M | $-244.7M | $-211.4M | $416.2M | $-151.6M | $50.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $9.5M | $15.9M | $12.9M | $17.8M | $8.5M | $3.1M | $17.9M | $3.4M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $255.3M | $-88.8M | $249.3M | $-141.4M | $-21.6M | $-623.2M | $147.7M | $-287.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $189.2M | $484.3M | $17.8M | $310.7M | $19.3M | $634.7M | $6.2M | $97.0M |
| Net Change in Cash | $31.9M | $47.9M | $-90.9M | $-75.4M | $-213.7M | $427.7M | — | — |
| Free Cash Flow | $-422.1M | $-363.6M | $-370.9M | $-262.5M | $-219.9M | $413.1M | $-169.5M | $46.7M |